Literature DB >> 4082574

Acquired heparinlike anticoagulant in a patient with metastatic breast carcinoma.

G M Rodgers, L Corash.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4082574      PMCID: PMC1306453     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


× No keyword cloud information.
  11 in total

1.  The anticoagulant effect of heparan sulfate and dermatan sulfate.

Authors:  A N Teien; U Abildgaard; M Höök
Journal:  Thromb Res       Date:  1976-06       Impact factor: 3.944

2.  A clinical study of the lupus anticoagulant.

Authors:  M A Schleider; R L Nachman; E A Jaffe; M Coleman
Journal:  Blood       Date:  1976-10       Impact factor: 22.113

3.  Heparin-like inhibitor of blood coagulation in normal newborn.

Authors:  A D Muller; J M van Doorm; H C Hemker
Journal:  Nature       Date:  1977-06-16       Impact factor: 49.962

Review 4.  Acquired inhibitors of blood coagulation.

Authors:  D I Feinstein; S I Rapaport
Journal:  Prog Hemost Thromb       Date:  1972

5.  Electrophoresis of acidic mucopolysaccharides in agarose gel.

Authors:  A A Horner
Journal:  Can J Biochem       Date:  1967-07

6.  Vessel proteoglycans and thrombogenesis.

Authors:  T N Wight
Journal:  Prog Hemost Thromb       Date:  1980

7.  Eosinophilic cytoplasmic inclusions in fetal leukocytes: are Auer bodies a recapitulation of fetal morphology?

Authors:  P E Newburger; T J Novak; R P McCaffrey
Journal:  Blood       Date:  1983-03       Impact factor: 22.113

8.  Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder.

Authors:  R N Palmer; M E Rick; P D Rick; J A Zeller; H R Gralnick
Journal:  N Engl J Med       Date:  1984-06-28       Impact factor: 91.245

9.  A heparin-like anticoagulant in an 8-month-old boy with acute monoblastic leukemia.

Authors:  J B Bussel; P G Steinherz; D R Miller; M W Hilgartner
Journal:  Am J Hematol       Date:  1984-01       Impact factor: 10.047

10.  Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder.

Authors:  M S Khoory; M E Nesheim; E J Bowie; K G Mann
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

View more
  4 in total

1.  A unique property of a plasma proteoglycan, the C1q inhibitor. An anticoagulant state resulting from its binding to fibrinogen.

Authors:  D K Galanakis; B Ghebrehiwet
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

2.  Management of rare acquired bleeding disorders.

Authors:  Marzia Menegatti; Eugenia Biguzzi; Flora Peyvandi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 3.  Laboratory evaluation of a bleeding patient.

Authors:  R O Wallerstein
Journal:  West J Med       Date:  1989-01

4.  Acquired heparin-like anticoagulation process in a patient with multiple myeloma: a case report and literature review.

Authors:  Haorui Shen; Chao Wu; Lijuan Chen; Run Zhang
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.